🔍

NATCOPHARM - Natco Pharma

📊 NSE: NATCOPHARM 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 10:18

📢 Recent Corporate Announcements

Natco Pharma Promoters Declare No Share Pledging for FY 2025-26

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Apr 2026, 05:30 PM

Natco Pharma has submitted a mandatory annual disclosure under Regulation 31(4) of the SEBI (SAST) Regulations for the financial year ended March 31, 2026. The promoter group, led by Sri V.C. Nannapaneni, has declared that no shares were encumbered or pledged, directly or indirectly, during this period. This routine filing confirms that the promoter's equity stake remains free of any new liens or financial obligations. Such disclosures are standard practice to ensure transparency regarding promoter shareholding stability.

Annual disclosure submitted under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Promoter V.C. Nannapaneni confirmed no encumbrances were made by the promoter group or Persons Acting in Concert (PAC).
The declaration covers the full financial year ending March 31, 2026.
Confirms the absence of any new pledges on promoter-held equity, maintaining status quo on ownership transparency.

💡 This is a routine regulatory compliance filing with no impact on company fundamentals; investors should focus on upcoming quarterly earnings and product pipeline updates.

Natco Pharma Files Quarterly SEBI Compliance Certificate for March 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Apr 2026, 10:51 AM

Natco Pharma Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations for the period ending March 31, 2026. The filing confirms that physical share certificates received for dematerialization were processed, mutilated, and cancelled as per regulatory requirements. The company's records have been updated to reflect NSDL and CDSL as the registered owners within the mandatory 15-day timeframe. This is a standard administrative procedure to ensure the integrity of electronic shareholding.

Compliance certificate submitted for the quarter ended March 31, 2026.
Confirmation of dematerialization processing within the statutory 15-day limit.
Verification and cancellation of physical certificates completed by Venture Capital and Corporate Investments Private Limited.

💡 This is a routine regulatory filing with no impact on the company's financial performance or business operations. No action is required from investors.

Natco Pharma Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 31 Mar 2026, 01:57 PM

Natco Pharma Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting April 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's financial results. The window will remain closed until 48 hours after the declaration of the financial results for the quarter and year ending March 31, 2026. The specific date for the board meeting to approve these results will be communicated at a later date.

Trading window closure effective from April 1, 2026.
Closure applies to Directors, Designated Persons, and all connected persons.
Window to remain shut until 48 hours post-declaration of Q4 and FY26 financial results.
Compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 This is a routine regulatory filing with no direct impact on stock price; investors should monitor for the upcoming announcement of the board meeting date for financial results.

Natco Pharma Approves Demerger of Agrochemicals Business; 1:1 Share Entitlement Ratio

🟢 POSITIVE ⭐ 8/10

M&A 📅 24 Mar 2026, 05:14 PM

Natco Pharma has approved the demerger of its Agrochemicals division into a separate listed entity, Natco Crop Health Sciences Limited. Shareholders will receive one share of the new company for every one share held in Natco Pharma, resulting in an 80% direct ownership stake for existing shareholders. The Agrochemicals division is currently a small part of the business, contributing ₹60.62 crore (1.48%) to the total turnover in FY25. The company also announced a new $100,000 investment in Nigeria and the liquidation of its non-viable Australian subsidiary.

Demerger of Agrochemicals business into Natco Crop Health Sciences Limited with a 1:1 share ratio.
Agrochemicals division turnover was ₹60.62 crore in FY25, representing 1.48% of total revenue.
Post-demerger, shareholders will hold 80% direct stake and 20% indirect stake via Natco Pharma in the new entity.
Incorporation of a new wholly owned subsidiary in Nigeria with an investment up to $100,000.
Liquidation of Australian subsidiary Natco Pharma Australia Pty Ltd expected by September 2026.

💡 Investors should welcome this move as it aims to unlock value and provide a focused growth platform for the agrochemical business. No immediate action is needed as the demerger process involves multiple regulatory approvals and has an appointed date of October 1, 2026.

Natco Pharma Launches Generic Semaglutide in India at MRP Starting INR 1,290

🟢 POSITIVE ⭐ 9/10

EXPANSION 📅 20 Mar 2026, 09:31 AM

Natco Pharma has announced the launch of generic Semaglutide injection in India, timed precisely with the patent expiry. The company is the first to introduce this GLP-1 therapy in multi-dose vials, priced aggressively at an MRP starting from INR 1,290, which is approximately 90% cheaper than the innovator's brand. This move aims to significantly increase patient accessibility for Type 2 diabetes treatment. Additionally, Natco plans to launch a pen device variant in April 2026, priced between INR 4,000 and INR 4,500.

Launch of generic Semaglutide (SEMANAT™ and SEMAFULL™) on Day 1 of patent expiry.
Pricing for multi-dose vials starts at INR 1,290, representing a 90% discount to the innovator brand.
Pen device launch scheduled for April 2026 with MRP ranging from INR 4,000 to INR 4,500.
First company to offer generic Semaglutide in vial dosage form in the Indian market.
Strategic move to offer the product to third parties for co-marketing to enhance market penetration.

💡 Investors should monitor the sales trajectory of this blockbuster molecule as Natco's aggressive pricing could lead to significant market share gains in the Indian diabetes segment. This launch reinforces Natco's strategy of being a first-mover in high-value generic opportunities.

Natco Pharma to Participate in Investec Promoter and Founder Conference on March 9, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Mar 2026, 10:23 AM

Natco Pharma Limited has scheduled an institutional investor meeting for March 9, 2026, in Mumbai. The company will be participating in the Investec Promoter and Founder Conference 2026 from 9:00 AM to 5:00 PM. The interactions are planned as in-person and group meetings with various institutional investors. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during these interactions.

Participation in Investec Promoter and Founder Conference 2026 on March 9, 2026.
Meeting window scheduled between 9:00 AM and 5:00 PM in Mumbai.
Format includes in-person and group interactions with institutional investors.
Disclosure made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 Investors should monitor for any post-conference presentations or transcripts that may provide insights into management's outlook. No immediate action is required as this is a routine investor relations activity.

Natco Pharma Confirms Semaglutide Partnership with Eris Lifesciences for March 2026 Launch

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 25 Feb 2026, 10:02 AM

Natco Pharma has confirmed its partnership with Eris Lifesciences for the marketing of the weight-loss drug Semaglutide in India. The company received CDSCO approval for the drug on February 14, 2026, and is preparing for a commercial launch in March 2026. While the company stated the partnership is in the ordinary course of business with no immediate material financial impact, it marks a significant entry into the high-growth GLP-1 segment. Natco is currently working with multiple marketing partners to facilitate this upcoming domestic launch.

Received CDSCO approval for Semaglutide in India on February 14, 2026
Confirmed marketing partnership with Eris Lifesciences for the weight-loss drug
Product launch in the Indian market scheduled for March 2026
Company clarified that negotiations are part of ordinary business operations

💡 Investors should monitor the revenue contribution from the Semaglutide launch starting Q1 FY27, as this segment represents a major growth opportunity. The ability to scale through multiple marketing partners like Eris could provide a competitive edge in the domestic market.

Natco Pharma Proposes Reappointment of CMD and CEO with Salary Caps up to ₹1.95 Crore

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 20 Feb 2026, 01:03 PM

Natco Pharma is seeking shareholder approval via postal ballot for the reappointment of four key executive directors for a one-year term starting April 2026. The proposal includes Chairman V.C. Nannapaneni with a salary cap of ₹1.95 crore and CEO Rajeev Nannapaneni at ₹1.80 crore, both eligible for a 1% profit commission. Additionally, two other senior directors are proposed for reappointment with salaries up to ₹1.93 crore each. This move ensures leadership stability for the upcoming fiscal year while maintaining performance-linked incentives.

Proposed reappointment of CMD V.C. Nannapaneni for 1 year with ₹1.95 crore salary plus 1% profit commission
Proposed reappointment of CEO Rajeev Nannapaneni for 1 year with ₹1.80 crore salary plus 1% profit commission
Directors P.S.R.K. Prasad and Dr. D. Linga Rao proposed for 1-year terms with salaries up to ₹1.93 crore each
Shareholder e-voting period scheduled from February 23, 2026, to March 24, 2026
Remuneration includes special incentives ranging from 20% to 100% of salary depending on the role

💡 Investors should monitor the voting results to ensure leadership continuity; the short one-year tenure suggests a near-term review of leadership roles or potential succession planning.

Natco Pharma Q3 PAT at ₹151.3 Cr; Zero Revlimid Revenue; Eyes Large M&A with ₹2,500 Cr Cash

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 18 Feb 2026, 03:35 PM

Natco Pharma reported a consolidated revenue of ₹705.4 crores for Q3 FY26, showing resilience despite zero revenue contribution from Revlimid during the quarter. The company is successfully pivoting towards emerging markets like Brazil and Canada while integrating its 35.75% stake in Adcock Ingram, which is expected to contribute ₹35-40 crores to quarterly PAT. Management is actively pursuing 1-2 large acquisitions using its ₹2,500 crore cash reserve and expects GLP-1 (Semaglutide) approval for the Indian market shortly. Additionally, the de-merger of the Crop Health Sciences business is on track for completion within the next 8-9 months.

Consolidated revenue grew to ₹705.4 crores in Q3 FY26 compared to ₹651.1 crores in the previous year.
Maintained an EBITDA margin of 30.7% with a net profit of ₹151.3 crores despite zero Revlimid contribution.
Adcock Ingram acquisition expected to add approximately ₹35-40 crores to quarterly PAT moving forward.
Company holds a net cash position of ₹2,500 crores, earmarked for 1-2 large-scale acquisitions in 2026.
GLP-1 (Semaglutide) launch in India is imminent following expected DCGI approval and a fill-finish tie-up with OneSource.

💡 Investors should monitor the progress of the Crop Health de-merger and the upcoming GLP-1 launch in India as key growth catalysts. The successful transition from Revlimid dependency to a diversified emerging market model strengthens the long-term investment case.

Natco Pharma Receives CDSCO Approval for Generic Semaglutide Injection in India

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 14 Feb 2026, 09:31 AM

Natco Pharma has received regulatory approval from the CDSCO to manufacture and market generic Semaglutide injection in India. The drug is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus. The company plans to launch the product in the domestic market in March 2026. This approval allows Natco to enter the high-demand GLP-1 receptor agonist segment, diversifying its portfolio beyond its traditional strength in oncology.

Received CDSCO approval to manufacture and market generic Semaglutide injection in India
Commercial launch scheduled for the Indian market in March 2026
Product targets the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise
Leverages Natco's existing infrastructure of 9 manufacturing sites and 2 R&D facilities

💡 Investors should view this as a significant portfolio expansion into the chronic care segment. Monitor the company's pricing strategy and market penetration following the March 2026 launch.

Natco Pharma Receives USFDA EIR with VAI Status for Chennai API Unit

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 13 Feb 2026, 09:18 AM

Natco Pharma has received the Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility in Manali, Chennai. The inspection, which took place from November 17 to November 21, 2025, had originally resulted in seven Form-483 observations. The USFDA has now classified the inspection as Voluntary Action Indicated (VAI), meaning the facility is considered to be in a state of compliance. This resolution is a significant positive as it clears the path for future product approvals from this site.

Received Establishment Inspection Report (EIR) for the Chennai API unit from the USFDA.
The inspection conducted in November 2025 resulted in 7 observations in Form-483.
USFDA has officially classified the inspection status as Voluntary Action Indicated (VAI).
The VAI status confirms that the facility meets regulatory standards despite the initial observations.
Clears regulatory hurdles for the API division which supports the company's oncology and specialty generic portfolio.

💡 Investors should view this as a positive development that mitigates regulatory risk for Natco's API supply chain. The stock may see a positive reaction as the VAI status allows for uninterrupted business and new product approvals from the Chennai site.

Natco Pharma Releases Audio Recording of Q3 FY25-26 Earnings Conference Call

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 12 Feb 2026, 06:03 PM

Natco Pharma Limited has released the audio recording of its earnings conference call for the quarter and nine months ended December 31, 2025. The call was held on February 12, 2026, following the announcement of the company's Q3 FY26 financial results. This disclosure is a standard regulatory requirement under SEBI (Listing Obligations and Disclosure Requirements) Regulations. The recording provides investors with access to management's commentary on the company's operational performance and future outlook.

Audio recording of Q3 FY25-26 earnings call made available on the company website.
The conference call was conducted on February 12, 2026, at 16:00 Hrs IST.
Filing complies with Regulation 30 and 46 of SEBI LODR Regulations, 2015.
Recording covers performance for the nine-month period ending December 31, 2025.

💡 Investors should listen to the recording to gain insights into management's commentary on product pipelines and market challenges. No immediate action is required as this is a routine administrative disclosure.

Natco Pharma Declares 3rd Interim Dividend of Rs 1.50 per Share; Record Date Feb 18

🟢 POSITIVE ⭐ 7/10

DIVIDEND 📅 12 Feb 2026, 03:49 PM

Natco Pharma Limited has declared its third interim dividend of Rs 1.50 per equity share for the financial year 2025-26. This dividend represents a 75% payout on the face value of Rs 2 per share. The company has fixed February 18, 2026, as the record date to identify eligible shareholders for this payout. The distribution of the dividend is scheduled to begin on February 26, 2026.

3rd interim dividend of Rs 1.50 per equity share (75% of face value) declared for FY 2025-26
Record date for dividend eligibility is set for February 18, 2026
Dividend payment process will commence from February 26, 2026
Announcement follows the Board of Directors meeting held on February 12, 2026

💡 Investors interested in the dividend must own the shares before the ex-dividend date. Existing shareholders should verify their bank details are updated for seamless credit.

Natco Pharma Q3 PAT Up 14% YoY to ₹1,513M; Declares ₹1.50 Dividend & Chile Expansion

🔵 WATCH ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 03:48 PM

Natco Pharma reported a 14% YoY increase in consolidated net profit to ₹1,513 million for Q3 FY26, despite a significant sequential decline from Q2. The company declared a third interim dividend of ₹1.50 per share and announced the incorporation of a new subsidiary in Chile. A major milestone was the completion of the 35.75% stake acquisition in South Africa's Adcock Ingram for approximately $225 million. Additionally, the company is evaluating a demerger of its Agro Chemicals business and has appointed Amit Parekh as the new CFO.

Consolidated Revenue from operations grew 36% YoY to ₹6,473 million, though down from ₹13,630 million in Q2.
Declared third interim dividend of ₹1.50 per share (75% of face value) with record date of Feb 18, 2026.
Completed acquisition of 35.75% stake in Adcock Ingram Holdings (South Africa) for ZAR 3,873 million (~$225 million).
Approved incorporation of a wholly-owned subsidiary in Chile with an investment of up to $300,000.
Appointed Amit Parekh as CFO effective Feb 13, 2026, following the superannuation of S.V.V.N. Appa Rao.

💡 Investors should monitor the integration of the Adcock Ingram acquisition and the potential value unlocking from the proposed Agro Chemicals demerger. While YoY growth is positive, the high sequential volatility in earnings warrants a cautious approach to quarterly performance expectations.

Natco Pharma Appoints Amit Parekh as CFO and Kalakuntla Srinivas Rao as EVP Pharma Division

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 12 Feb 2026, 03:45 PM

Natco Pharma has announced a key leadership transition where Mr. Amit Parekh will take over as the Chief Financial Officer effective February 13, 2026, following the superannuation of Mr. S.V.V.N. Appa Rao. Mr. Parekh, currently an internal candidate, brings over 23 years of experience including a significant tenure at Dr. Reddy's Laboratories. Simultaneously, the company has appointed Mr. Kalakuntla Srinivas Rao as Executive Vice President of the Pharma Division, leveraging his 25+ years of experience in global regulatory compliance and operations. These appointments reflect a strategic move to bring in seasoned industry veterans to lead financial and operational functions.

Mr. Amit Parekh appointed as CFO effective February 13, 2026, succeeding Mr. S.V.V.N. Appa Rao.
Incoming CFO Amit Parekh has over 23 years of experience in finance, M&A, and digital transformation.
Mr. Kalakuntla Srinivas Rao appointed as EVP - Pharma Division effective February 12, 2026.
New EVP brings 25+ years of experience with expertise in USFDA, PMDA, and MHRA compliance.
Leadership team strengthened with former executives from Dr. Reddy's, MSN Laboratories, and Lupin.

💡 Investors should view this as a routine but important management transition; the internal promotion of the CFO suggests financial continuity while the new EVP brings valuable regulatory expertise.

View All NATCOPHARM Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total consolidated revenue grew 15.9% YoY to INR 4,784 Cr in FY25 from INR 4,126.9 Cr in FY24. The Pharmaceutical segment remains the primary driver, while the Crop Health Sciences (Agrochemicals) segment contributed INR 59.8 Cr in FY25, a decline from INR 108.3 Cr in FY24. Q2 FY26 revenue stood at INR 1,463 Cr, a marginal 1.9% increase over Q2 FY25.

Geographic Revenue Split

The company exports to over 50 countries. Key markets include the US (driven by gRevlimid profit sharing), India (domestic oncology), and emerging markets like Brazil and Canada which showed healthy growth. New product filings have commenced in Latin America, with expansion planned for Saudi Arabia, Algeria, Morocco, and Egypt.

Profitability Margins

Operating Profit Margin (OPM) improved to 49.6% in FY25 from 43.9% in FY24. However, margins contracted to 42.7% in H1 FY26 due to pricing pressures in the US and domestic markets and higher R&D provisions. PAT margin stood at 39.4% in FY25 compared to 33.6% in FY24.

EBITDA Margin

EBITDA margin was 53.3% in FY25, up from 45.5% in FY24. For Q2 FY26, the EBITDA margin was reported at 46.4% with an absolute EBITDA of INR 679.2 Cr, reflecting a moderation from FY25 peaks as the gRevlimid patent expiry approaches.

Capital Expenditure

The company has planned a total capex of INR 800 Cr for FY26 and FY27 combined. This includes maintenance and expansion capex of approximately INR 250-300 Cr per annum to support new product launches and capacity optimization.

Credit Rating & Borrowing

Maintains a robust financial profile with a TD/OPBITDA of 0.1 times as of September 2025. Interest coverage was exceptionally high at 91.9 times in FY25. The company has a negative net debt position with cash reserves of approximately INR 3,200 Cr as of September 30, 2025.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (APIs) for oncology, diabetic, and anti-infective segments. The company is backward-integrated for several key formulations, though specific chemical names and their % of total cost are not disclosed.

Import Sources

Not specifically disclosed, but the company operates with a global supply chain to mitigate risks for high-lead-time products.

Capacity Expansion

Current capacity is not disclosed in MT/units, but the company is expanding its presence in emerging markets and agrochemicals. Capex of INR 800 Cr is earmarked for FY26-27 to support this expansion.

Raw Material Costs

Raw material costs are managed through backward integration in APIs. The company maintains high inventory levels (193 days in Sept 2025) to mitigate supply chain challenges for high-value products.

Manufacturing Efficiency

The company focuses on optimizing production schedules to minimize switchover costs at plants that manufacture multiple APIs or formulations.

Logistics & Distribution

Not disclosed as a specific % of revenue, but international expansion into Brazil, Canada, and China has led to higher receivables periods.

📈 Strategic Growth

Expected Growth Rate

10-15%

Growth Strategy

Growth will be driven by the launch of Semaglutide (March 2026), expansion into the MENA region (Saudi Arabia, Egypt), and the INR 2,000 Cr acquisition of a stake in AIHL in November 2025. The company is also focusing on niche Para IV filings and diversifying into Agrochemicals.

Products & Services

Oncology formulations, gRevlimid (Lenalidomide), Semaglutide (diabetic segment), anti-infectives, APIs, and Agrochemical products (Crop Health Sciences).

Brand Portfolio

Natco, gRevlimid (generic version).

New Products/Services

Planned launch of Semaglutide 2.4 MG injection in March 2026. New launches in oncology, diabetic, and anti-infective segments are expected to offset pricing pressures.

Market Expansion

Targeting expansion in Saudi Arabia, Algeria, Morocco, and Egypt. Increasing focus on Brazil, Canada, Southeast Asia, and China.

Market Share & Ranking

Leading player in the domestic oncology segment in India.

Strategic Alliances

Strategic partnerships are used for global expansion and niche molecule development; specific partner names for recent JVs were not disclosed.

🌍 External Factors

Industry Trends

The industry is shifting toward complex generics and specialty medicines. Natco is positioning itself by moving into peptides (Semaglutide) and agrochemicals to diversify away from pure generic pricing wars.

Competitive Landscape

Key competitors include Novo Nordisk and Emcure (specifically in the Semaglutide market). The US market remains highly competitive with intense pricing pressure.

Competitive Moat

Moat is built on strong R&D capabilities in complex generics and backward integration in APIs. This is sustainable due to high entry barriers in oncology and complex molecules, though patent expiries (gRevlimid) pose a recurring challenge.

Macro Economic Sensitivity

Sensitive to healthcare regulatory changes and inflationary pressures which impacted OPM in 9M FY25.

Consumer Behavior

Shift toward affordable complex generics in emerging markets and increasing demand for diabetic treatments (GLP-1 analogues).

Geopolitical Risks

Exposure to trade barriers and regulatory scrutiny in 50+ export countries, including potential impacts from US-China trade dynamics affecting API sourcing.

⚖️ Regulatory & Governance

Industry Regulations

Subject to USFDA inspections, cGMP compliance, and price controls in the domestic Indian market. Regulatory scrutiny and compliance costs are noted as increasing risks.

Environmental Compliance

Not disclosed in absolute INR values, but the company adheres to cGMP norms and high-quality standards.

Legal Contingencies

The company is involved in Para IV patent litigations in the US. While specific case values are not disclosed, these litigations are critical for maintaining the exclusivity of products like gRevlimid.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the extent of revenue moderation following the gRevlimid patent expiry in Q2 FY26. Regulatory risks from USFDA audits could impact export capabilities.